Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-world study reveals how many hive patients need a xolair boost

NCT ID NCT04583475

First seen Jan 06, 2026 · Last updated May 25, 2026 · Updated 16 times

Summary

This study looked at 163 adults with chronic spontaneous urticaria (long-term hives) to see how many needed a higher dose or more frequent injections of the drug Xolair (omalizumab) after 3 months. Researchers simply observed what doctors prescribed in real life, without giving any treatment themselves. The goal was to understand real-world treatment patterns, not to test a new therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPONTANEOUS URTICARIA, CHRONIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hop Claude Huriez Chu Lille

    Lille, 59037, France

Conditions

Explore the condition pages connected to this study.